Atlanta
,
USA
4 - 7 November 2025
The Obesity Society (Obesity Week 2025)
Presentation schedule and materials
Tuesday, 04 November 2025
19:30
- 20:30
ET
P-135
POSTER
Real-World Physician and Patient Perspectives on Compliance and Adherence of Semaglutide for Obesity or Overweight
Yiqiao Zhang1; Zhenxiang Zhao1; Andrea Leith2; Sophie Barlow2; Bríain Ó Hartaigh1; Anthony Fabricatore1
MATERIALS AVAILABLE
19:30
- 20:30
ET
P-134
POSTER
Factors Related to Adherence and Compliance in Patients With Overweight or Obesity Receiving Semaglutide for Weight Management
Yiqiao Zhang1; Zhenxiang Zhao1; Andrea Leith2; Sophie Barlow2; Bríain Ó Hartaigh1
MATERIALS AVAILABLE
19:30
- 20:30
ET
P-111
POSTER
Efficacy of oral semaglutide 25 mg in people with overweight or obesity and poor physical function
Domenica Rubino1; Oscar Birkhan2; W. Timothy Garvey3; Ildiko Lingvay4; Naveen Rathor2; Chaithra Shaji5; Sean Wharton6,7,8,9
MATERIALS AVAILABLE
19:30
- 20:30
ET
P-097
POSTER
Semaglutide effect on physical functioning in adults with obesity and knee osteoarthritis
Henning Bliddal1; Harold Bays2; Johan Jendle3; Kristoffer Jensen Kolnes4; Thomas Hoffmann Morville4; Chaithra Shaji5; Sean Wharton6,7,8,9
MATERIALS AVAILABLE
19:30
- 20:30
ET
P-194
POSTER
Association between body mass index and surgeries for knee and hip joint replacements
Arunima Hait1; Inger Smith2; Timothy Arnaut3
MATERIALS AVAILABLE
19:30
- 20:30
ET
P-193
POSTER
Changes in alcohol and tobacco spending among users and non-users of semaglutide for weight management
Timothy Arnaut1; Katya Kazantseva2; Kajsa Kvist1; Bríain Ó Hartaigh3
MATERIALS AVAILABLE
Wednesday, 05 November 2025
08:15
- 08:30
ET
Oral-026
ORAL PRESENTATION
Improvements in Glycemic Parameters and Cardiovascular Risk Factors with Oral Semaglutide 25 mg
Domenica Rubino1; Oscar Birkhan2; W. Timothy Garvey3; Naveen Rathor2; Chaithra Shaji4; Sean Wharton5,6,7,8; Ildiko Lingvay9
MATERIALS AVAILABLE
08:30
- 08:45
ET
Oral-027
ORAL PRESENTATION
Real-World Impact of Semaglutide on Healthcare Utilization and Economic Outcomes in the United States
Prachi Arora, PhD1; Firas Dabbous, PhD2; Sariya Udayachalerm, PhD2; Cynthia Saiontz-Martinez, MSc2; Zhenxiang Zhao, PhD1; Bríain Ó Hartaigh, PhD1; Anthony Fabricatore, PhD1; Matthew Bassan, DO, Dipl AOBFP, CAQSM, Dipl ABOM1; Sara Alvarez, PharmD, MS1; Angela Fitch, MD, FACP, FOMA, Dipl ABOM3
MATERIALS AVAILABLE
14:30
- 15:30
ET
P-316
POSTER
Semaglutide Reduces Body Weight Regardless of Menopause Status: STEP and OASIS 4 Post Hoc Analysis
Maria Daniela Hurtado Andrade1; Rebecca Dunsmoor-Su2; Emilia Huvinen3; Naveen Rathor4; Nanette Santoro5; Lauren Wilson6; Sushmita Yaganti6; Santiago Palacios7
MATERIALS AVAILABLE
14:30
- 15:30
ET
P-319
POSTER
CagriSema Reduces hsCRP in Adults With Overweight or Obesity: the REDEFINE 1 Trial
Pam R Taub1; Matthias Blüher2; Morten Böttcher3; Paul Brown4; Paolo Sbraccia5; Lærke Smedegaard4; Rasmus Sørrig4; John PH. Wilding6; Ildiko Lingvay7
MATERIALS AVAILABLE
14:30
- 15:30
ET
P-334
POSTER
Oral vs. Injectable Semaglutide: An Indirect Treatment Comparison of Weight Loss Outcomes
Molly Plotkin3; Milana Ivkovic2; Inger Smith1; Naveen Rathor2; Rohan Chowdhury4; Alexander Hodkinson4
MATERIALS AVAILABLE
15:30
- 15:45
ET
Oral-055
ORAL PRESENTATION
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: the REDEFINE 1 Trial
Subodh Verma1; Morten Böttcher2; Paul Brown3; Dror Dicker4; Domenica Rubino5; Paolo Sbraccia6; Arya M. Sharma7; Lærke Smedegaard3; Rasmus Sørrig3; W. Timothy Garvey8
MATERIALS AVAILABLE
15:45
- 16:00
ET
Oral-056
ORAL PRESENTATION
Effect of CagriSema 2.4mg/2.4mg on Body Composition, Muscle Strength & Physical Function
Eric Ravussin1; Cynthia Karenina Osorto Contreras2; Gema Frühbeck3; Christoffer Andersen Hagemann2; Alexander D. Miras4; John Morton5; Niels Zeuthen2; Carla M. Prado6
MATERIALS AVAILABLE
16:00
- 16:15
ET
Oral-057
ORAL PRESENTATION
REDEFINE 5: CagriSema in East Asian Adults With Overweight or Obesity, With or Without T2D
Yasushi Ishigaki1; Niels-Peter Becker2; Christoffer Andersen Hagemann2; Kuo-Chin Huang3; Arihiro Kiyosue4; Soo Lim5; Yukiko Onishi6; Ananda Kosuvaripalli2; Tomoko Takano7; Toshimasa Yamauchi8
MATERIALS AVAILABLE
16:15
- 16:30
ET
Oral-058
ORAL PRESENTATION
Effect of semaglutide 2.4 mg in Chinese adults with overweight or obesity (BMI ≥24 or ≥28): STEP 12
Lixin Guo1; Xiaolei Bao2; Kristoffer Jensen Kolnes3; Christian Laugesen3; Yibing Lu4; Bifen Luo2; Guoyue Yuan5; Robert Kushner6
MATERIALS AVAILABLE
16:30
- 16:45
ET
Oral-059
ORAL PRESENTATION
STEP UP: efficacy of semaglutide in obesity treatment targets and cardiovascular risk thresholds
Carel W le Roux1,2; W. Timothy Garvey3; Kristoffer Jensen Kolnes4; Jøran Hjelmesæth5; Ildiko Lingvay6; Niklas Kahr Rasmussen4; Volker Schnecke4; Luca Busetto7
MATERIALS AVAILABLE
16:45
- 17:00
ET
Oral-060
ORAL PRESENTATION
Lower Real-World Risk of Cardiovascular Events With Semaglutide 2.4 mg in People with Risk Factors for Atherosclerotic Cardiovascular Disease: Results from SCORE – Primary Prevention Population study
Victoria Divino1; Zhenxiang Zhao1; Kim G. Smolderen2,3; Carlos Mena-Hurtado2; Yan Chen4; Joanna Boland4; Jinlin Song4; Briain O Hartaigh1; B. Gabriel Smolarz1; Filip K. Knop5; Michael G. Nanna2
MATERIALS AVAILABLE
Thursday, 06 November 2025
14:30
- 15:30
ET
P-711
POSTER
CagriSema Reduces Predicted ASCVD Risk in Adults With Overweight or Obesity: the REDEFINE 1 Trial
Subodh Verma1; Morten Böttcher2; Paul Brown3; Dror Dicker4; Domenica Rubino5; Paolo Sbraccia6; Arya M. Sharma7; Lærke Smedegaard3; Rasmus Sørrig3; W. Timothy Garvey8
MATERIALS AVAILABLE
14:30
- 15:30
ET
P-478
POSTER
CagriSema and achievement of BMI and waist-to-height ratio treatment targets: REDEFINE 1
Luca Busetto1; Cynthia Karenina Osorto Contreras2; Mikkel Hovden Christensen2; Deborah Horn3; Carel W. le Roux4,5; Barbara McGowan6; Claire Prener Miller2; W. Timothy Garvey7
MATERIALS AVAILABLE
14:30
- 15:30
ET
P-663
POSTER
POEM-Gulf: Prevalence and economic burden of obesity-related comorbidities in the Gulf region
Noor Al Busaidi1; Mohammad N Alajmi2; Mohamed Aly Elsherif3; Fadhila Al Busaidi4; Asrar Alsayed Hashem5; Amira Nasser Al Kharusi6; Sulaiman Almazeedi7; Tarik A Elhadd8; Amin Jayyousi9; Rayaz A Malik10; Prakash Shanmugam11; Malek Arjoub12; Mohammad El Taweel12; Guruprasad Subbarao12; Fahad Al Ajmi13
MATERIALS AVAILABLE
14:30
- 15:30
ET
P-603
POSTER
STEP UP: Final dose responder analysis in participants randomized to semaglutide 7.2 mg
W. Timothy Garvey1; Jøran Hjelmesæth2; Kristoffer Jensen Kolnes3; Shilpa M4; Niklas Kahr Rasmussen3; Julio Rosenstock5; Ildiko Lingvay6
MATERIALS AVAILABLE
Keywords